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The Pharmacokinetic characteristic of ketamine, particularly the shift from the epidu-
ral space to the cerebrospinal ﬂuid (CSF), is still unclear.  Furthermore pharmacokinetic 
differences between racemic ketamine and S(+)-ketamine are not clearly described when 
administered into the epidural space.  We measured plasma and CSF concentrations of 
racemic ketamine and S(+)-ketamine after 2 mg/kg intravenous or 2 mg/kg epidural in-
jection in 32 rabbits, and calculated pharmacokinetic parameters by the moment analy-
sis method.  The elimination half time of S(+)-ketamine was signiﬁcantly shorter than 
that of racemic ketamine and the systemic distribution volume of S(+)-ketamine was 
signiﬁcantly smaller than that of racemic ketamine in the CSF.  Pharmacokinetic param-
eters in the CSF after epidural injection of racemic versus S(+)-ketamines were: maxi-
mum concentration,  0.4 ± 0.1 versus 0.6 ± 0.2 µg/mL (not signiﬁcant); time to maximum 
concentration, 9.7 ± 2.1 versus 9.0 ± 3.4 min (not signiﬁcant); elimination half time, 127.1 
± 25.2 versus 89.3 ± 19.4 min (P = 0.005); area under the curve, 56.4 ± 6.4 versus 56.6 
± 11.0 µg•mL/min (not significant); and distribution volume, 19463.5 ± 3266.1 versus 
13613.3 ± 4895.2 mL (P = 0.014), respectively.  When injected intravenously, there was 
no significant difference in these parameters of the CSF between racemic and S(+)-
ketamines.  Racemic ketamine passed easily through the blood brain barrier when ad-
ministered intravenously.  It also shifted to the CSF through the systemic circulation, 
even when they were administered epidurally.  S(+)-Ketamine had similar movement as 
racemic ketamine.
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Ketamine has been used widely as a sole anesthetic 
when injected intravenously and as an adjuvant 
analgesic agent with local anesthetics when admin-
istered epidurally (Islas et al., 1985; Naguib et al., 
1986; Ravat et al., 1987).  However, it is still debat-
able that the experimental and clinical effects of 
Abbreviations:  AUC, area under the curve; BBB, blood brain barrier; BP, blood pressure; Cmax, maxmam concen-
tration; CSF, cerebrospinal ﬂuid; HPLC, high-performance liquid chromatography; HR, heart rate; T1/2β, elimina-
tion half life; Tmax, time to maximum concentration; Vdss, distribution volume
epidural ketamine on the intensity of somatic and 
visceral pain (Subramaniam et al., 2001). One of 
the major issues behind this debate is the uncer-
tainty regarding pharmacokinetics, especially the 
transfer of ketamine into the cerebrospinal fluid 
(CSF), that is, the pharmacokinetics of transfer 
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from the epidural space to the CSF across the dura 
mater and from the systemic circulation to the CSF 
through the blood brain barrier (BBB).  Pedraz et 
al. (1991) reported in the dog model that ketamine 
easily crosses the dura mater due to its lipid solubil-
ity when administered epidurally.  However, there 
is a report that epidurally administered ketamine 
does not work at a segmental action (Horiuchi 
et al., 1991).  Moreover, there are no reports of a 
spinal segmental action for epidural ketamine, al-
though epidurally administered lipid-soluble drugs 
such as fentanyl are known to produce apparent 
spinal segmental actions (Dos Santos et al., 1996; 
Schols et al., 1996; Bernards et al., 2003a; 2003b). 
We hypothesized that epidurally administered ket-
amine is rapidly absorbed into the systemic circula-
tion and shifts into the intrathecal space through 
the BBB.  This will also explain the non-segmental 
action of ketamine. 
 Racemic ketamine consists of 2 optical iso-
mers, S(+)-ketamine and R(-)-ketamine and it 
is known that analgesic and sedative actions of 
the S(+)-ketamine is much stronger, resulting in 
widely clinical use in Europe (Geisslinger et al., 
1991; Kharasch et al., 1992; Arendt-Nielsen et al., 
1996; Murata et al., 2000).  However precise phar-
macokinetic study has not be elucidated regarding 
differences in S(+)-ketamine and R(-)-ketamines 
when administered in the epidural space. If phar-
macokinetic parameters of S(+)-ketamine and 
R(-)-ketamines are widely different, the local 
action of epidural ketamines may be segregated. 
To test these hypothesis, the pharmacokinetics of 
ketamine in the CSF were studied by intravenous 
and epidural administrations of racemeic and S(+)-
ketamines.
Materials and Methods
Anesthesia
Female Japanese white rabbits weighting 2.6 to 3.5 
kg were used. The whole experimental procedure 
using the animals was approved by the Tottori 
University institutional animal care committee. 
Pentobarbital (Abbott, Chicago, IL), 50 mg/kg, was 
administered through a 24 G stabilized catheter 
inserted into the ear vein to anesthetize the rab-
bit. Then, the rabbit was fixed in supine position 
and a tracheostomy was performed.  Anesthesia 
was maintained with 1 to 2% sevoﬂurane in an air-
oxygen mixture (inspired oxygen concentration = 
0.4). The rabbit was ventilated mechanically at a 
respiratory rate of 40 breaths/min and tidal volume 
of 10 mL/kg using a ventilator for small animals 
(rodent ventilator model 683, Harvard Medical In-
struments, Cambridge, MA). 
Preparation of the rabbit
A 24 G catheter was inserted into the right femoral 
artery for blood sampling and for monitoring of 
blood pressure (BP) and heart rate (HR).  Another 
catheter was inserted into the right internal jugular 
vein for injection o f racemic ketamine or S(+)-
ketamine.  Lactated Ringer sʼ solution was infused 
at a rate of 10 ml/kg/h.  The rabbit was then turned 
into prone position and a laminectomy was per-
formed at either C2 or C3 level using the electric 
scalpel and the drill.  A 2 Fr catheter for collection 
of the CSF was inserted after conﬁrming of the lo-
cation of the arachnoid membrane according to the 
method of Tiscot et al. (1995).  The epidural space 
was punctured in the epidural administration group 
at the interspace between L5 and L6 with a 20 G 
Touhy needle according to the method of Taguchi 
et al. (1996) and an epidural catheter was advanced 
to 3 cm within the epidural space. 
Sample collection
After completion of the preparation, we put a 
30-min interval to stabilize arterial blood pressure, 
heart rate and end-tidal carbon dioxide tension 
within normal limits.  The vital signs were continu-
ously monitored and kept within the normal range 
throughout the study period. Either racemic ket-
amine or S(+)-ketamine (Alexis biochemicals, Lau-
sen, Switzerland) were administered at 2 mg/kg in 
a bolus through the epidural catheter in the epidural 
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Fig. 1.  Time course of concentrations of racemic ket-
amine in plasma and CSF following a bolus injection of 
2 mg/kg epidurally (a) and intravenously (b).  Closed 
squares represent plasma concentrations.  Closed circles 
represent CSF concentrations.  Data are expressed as 
mean ± SD.  These graphs represent concentration 
curves before pharmacokinetic analyzing.  *P < 0.05, 
plasma concentration versus CSF concentration. 
groups and injected as a bolus dose via the internal 
jugular vein in the intravenous groups. The arterial 
blood (1.5 mL) and CSF (0.2 mL) were simultane-
ously collected with heparinized syringes at 1, 3, 
5, 10, 15, 30, 60 and 120 min after administration 
of the test drug.  Both samples were centrifuged at 
3000 rpm at 0˚C and the supernatant was stored at 
–80˚C until analysis.  Indocyanine green pigment 
(0.5 ml) was injected through the epidural catheter 
to conﬁrm an adequate positioning of the epidural 
catheter in randomly selected rabbits.
Measurement
Racemic ketamine and S(+)-ketamine concentra-
tions in the plasma and CSF were measured by 
high-performance liquid chromatography (HPLC) 
(Shimadzu SPD-10A, SCL-10A, LC-10AD, PGU-
12A, CTO10A and CR-8A, Kyoto, Japan).  Chro-
matographic conditions were as follows: mobile 
phase, phosphate buffer:methanol:acetonitorile = 
7:2:1; velocity of mobile phase, 1.2 mL/min; tem-
perature, 45˚C; wavelength, 215 nm; and column, 
phenilcolumn.  Pharmacokinetic parameters, maxi-
mum concentration (Cmax), time to Cmax (Tmax), 
elimination half time (T1/2β), area under the curve 
(AUC) and distribution volume (Vdss) were calcu-
lated from the plasma and CSF concentrations of 
both racemic ketamine and S(+) ketamine by the 
moment analysis method using a pharmacokinetics 
data analysis software (PK Solutions, version 2.0, 
Montrose, CO).  
Statistics
Parametric data were analyzed by Student sʼ t-test. 
A P value less than 0.05 was considered statisti-
cally signiﬁcant.  All data were expressed as mean 
± SD.
Results
There were no signiﬁcant differences in the mean 
body weight among 4 study groups, and that for the 
epidural racemic ketamine group, epidural S(+)-
ketamine group, intravenous racemic ketamine 
group and intravenous S(+)-ketamine group was 3.0 
kg, 3.0 kg, 2.9 kg and 2.8 kg, respectively. There 
were no significant differences in homodynamic 
parameters (HR and BP).  Figure 1 shows the 
changes in the plasma and the CSF concentrations 
over time in both groups of racemic ketamine. 
Figure 2 also shows changes of concentration over 
time in both groups of S(+)-ketamine.  Plasma 
concentrations were significantly higher than the 
CSF concentrations throughout our study period in 
both racemic ketamine and S(+)-ketamine epidural 
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groups.  In intravenous groups, plasma concentra-
tions of racemic ketamine were signiﬁcantly higher 
than the CSF concentrations at the point of 1, 30, 60 
and 120 min.  Also plasma concentrations of S(+)-
ketamine were significantly higher than the CSF 
concentration at the point of 1, 10, 15, 30, 60 and 
120 min.
Pharmacokinetic parameters
When these agents were administered epidur-
ally, Cmax of racemic ketamine was significantly 
smaller than that of S(+)-ketamine, AUC of race-
mic ketamine was signiﬁcantly smaller than that of 
S(+)-ketamine and Vdss of racemic ketamine was 
significantly larger than that of S(+)-ketamine in 
the plasma.  In the CSF, T1/2β of racemic ketamine 
was signiﬁcantly longer than that of S(+)-ketamine 
and Vdss of racemic ketamine was significantly 
larger than that of S(+)-ketamine (Table 1).  On the 
other hand, when these drugs were injected intrave-
nously, T1/2β of racemic ketamine was signiﬁcantly 
Table 1.  Pharmacokinetic parameters in epidural administration
 Racemic ketamine S(+)-Ketamine P value
Plasma Cmax (µg/mL) 1.4 ± 0.5 2.1 ± 0.5 0.016*
 Tmax (min) 6.3 ± 2.8 8.3 ± 2.8 0.167
 T1/2β (min) 106.4 ± 27.8 85.3 ± 27.6 0.149
 AUC (µg•min/mL) 111.5 ± 22.8 247.3 ± 61.9 < 0.0001*
 Vdss (mL) 7754 ± 2172 2992 ± 1055 < 0.0001*
CSF Cmax (µg/mL) 0.4 ± 0.1 0.6 ± 0.2 0.055
 Tmax (min) 9.7 ± 2.1 9.0 ± 3.4 0.595
 T1/2β (min) 127.1 ± 25.2 89.3 ± 19.4 0.005*
 AUC (µg•min/mL)  56.4 ± 6.4 56.6 ± 11.0 0.958
 Vdss (mL) 19463 ± 3266 13613 ± 4895 0.014*
 Data are expressed as mean ± SD.  
 AUC, area under the curve; Cmax, peak concentration; CSF, cerebrospinal fluid; T1/2β, elimination half life; 
Tmax, time to peak concentration; Vdss, distribution volume. 
* P < 0.05 for intergroup comparison. 
Fig. 2.  Time course of concentrations of S(+)-ketamine in plasma and CSF following bolus injection of 2 mg/kg 
epidurally (a) and intravenously (b).  Closed squares represent plasma concentrations.  Closed circles represent CSF 
concentrations.  Data are expressed as mean ± SD.  These graphs represent concentration curves before pharmacoki-
netic analyzing.  *P < 0.05, plasma concentration versus CSF concentration.  
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longer than that of S(+)-ketamine and Vdss of race-
mic ketamine in the plasma was signiﬁcantly larger 
than that of S(+)-ketamine in the plasma (Table 2). 
Tmax was signiﬁcantly shorter when administered 
intravenously than when administered epidurally 
(P = 0.007) in the pharmacokinetic parameters on 
the shift to the CSF of racemic ketamine (Table 3). 
After completion of the experiments, the location 
of epidural catheter tip was conﬁrmed by staining 
of the epidural space from L1 to L6 level.
 
Discussion
The major findings were as follows: i) The CSF 
concentrations of both racemic ketamine and S(+)-
ketamine approximated to their plasma concen-
trations 3 min after intravenous administration. 
Thereafter their concentration curves over time in 
the CSF were similar to those in the plasma.  ii) 
The CSF concentration of both racemic ketamine 
and S(+)-ketamine were significantly lower than 
their plasma concentration after epidural adminis-
Table 2.  Pharmacokinetic parameters in intravenous administration
 Racemic ketamine S(+)-Ketamine P value
Plasma Cmax (µg/mL) 2.4 ± 1.0 1.7 ± 0.4 0.123
 T1/2β (min) 145.9 ± 56.6 87.6 ± 22.8 0.017*
 AUC (µg•min/mL) 87.8 ± 24.2 93.9 ± 17.2 0.571
 Vdss (mL)  11666 ± 4043 7287 ± 1583 0.013*
CSF Cmax (µg/mL) 0.6 ± 0.3 0.7 ± 0.2 0.625
 Tmax (min) 6.0 ± 2.6 5.6 ± 3.8 0.829
 T1/2β (min) 143.6 ± 34.8 120.1 ± 36.4 0.207
 AUC (µg•min/mL) 54.9 ± 16.6 56.9 ± 14.3 0.797
 Vdss (mL) 20523 ± 4762 16064 ± 3925 0.060
 Data are expressed as mean ± SD.  
 AUC, area under the curve; Cmax, peak concentration; CSF, cerebrospinal fluid; T1/2β, elimination half life; 
Tmax, time to peak concentration; Vdss, distribution volume. 
* P < 0.05 for intergroup comparison. 
Table 3.  Comparison of CSF concentrations of racemic ketamine and S(+)-ketamine between epi-
dural and intravenous groups
 Racemic ketamine S(+)-Ketamine P value
Plasma Cmax (µg/mL) 0.4 ± 0.1 0.6 ± 0.3 0.076
 Tmax (min) 9.7 ± 2.1 6.0 ± 2.6 0.007*
 T1/2β (min) 127.1 ± 25.0 143.6 ± 34.8 0.294
 AUC (µg•min/mL) 56.4 ± 6.4 54.9 ± 16.6 0.814
 Vdss (mL)  19463 ± 3266 20523 ± 4762 0.612
CSF Cmax (µg/mL) 0.6 ± 0.2 0.7 ± 0.2 0.302
 Tmax (min) 9.0 ± 3.4 5.6 ± 3.8 0.081
 T1/2β (min) 89.3 ± 19.4 120.1 ± 36.4 0.053
 AUC (µg•min/mL)  56.6 ± 11.0 56.9 ± 14.3 0.966
 Vdss (mL) 13613 ± 4895 16064 ± 3925 0.288
 Data are expressed as mean ± SD.  
 AUC, area under the curve; Cmax, peak concentration; CSF, cerebrospinal fluid; T1/2β, elimination half life; 
Tmax, time to peak concentration; Vdss, distribution volume. 
* P < 0.05 for intergroup comparison. 
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tration.  These ﬁndings indicate that intravenously 
administered ketamine rapidly and massively shifts 
into the CSF through the BBB.  Furthermore epi-
durally administered ketamine is rapidly absorbed 
into the systemic circulation through the epidu-
ral vessels and shifts into the CSF.  Increase in the 
CSF concentrations of racemic ketamine until 10 
min after epidural administration is considered to 
be conducted by the amount of ketamine, which 
shifted to the CSF across the BBB and penetrated 
into the CSF across the dura mater.  As AUC of ra-
cemic ketamine in the plasma is signiﬁcantly larger 
than that in the CSF (111.5 µg•min/mL in the plas-
ma versus 56.4 µg•min/mL in the CSF, P < 0.0001), 
amount of ketamine absorbed into the plasma from 
the epidural space is likely to be more than that 
absorbed directly into the CSF.  Taking rapid shift 
of racemic ketamine from the plasma to the CSF 
into consideration, we propose that shift from the 
plasma to the CSF across the BBB may play an im-
portant role in increase of the CSF concentration of 
racemic ketamine. 
 It has been still unclear how the intravenously 
administered ketamine shifts to the CSF across 
the BBB.  Furthermore, our results demonstrated 
that they shifted rapidly to the CSF across the BBB 
after an intravenous bolus injection.  Their CSF 
concentrations approximated to their plasma con-
centrations 3 min after intravenous administration, 
thereafter, their concentration curves over time in 
the CSF were similar to those in the plasma.  This 
is the ﬁrst report to indicate that both racemic ket-
amine and S(+)-ketamine rapidly get across the 
BBB. 
 Horiuchi et al. (1991) reported that racemic 
ketamine administered epidurally in rabbits showed 
none of the inhibition of somatosensory evoked 
eyelid microvibration produced by stimulation of 
sciatic and ulnar nerves, concluding that racemic 
ketamine administered into the epidural space did 
not produce spinal segmental action.  If racemic 
ketamine penetrated into the CSF through the dura 
mater and increased its concentration in the CSF 
more than that in the plasma as mentioned previ-
ously, somatosensory evoked potential would be 
inhibited by intrathecal racemic ketamine.  There-
fore, racemic ketamine unlikely shifts into the CSF 
through the dura mater in rabbits.  Moreover, there 
is no report on analgesic effect produced by epidu-
ral ketamine in dogs to our knowledge.  Our results 
and the above-mentioned phamacodynamic results 
suggested that the direct penetration to the CSF 
across the dura mater of racemic ketamine would 
be less in rabbits than that in dogs previously de-
scribed by Pedraz (Pedraz et al., 1991).
 In the comparison of racemic ketamine with 
S(+)-ketamine on pharmacokinetic analysis, S(+)-
ketamine showed a shorter elimination half time 
from the plasma and a smaller distribution volume 
in the plasma than racemic ketamine.  There were 
no significant differences in pharmacokinetic pa-
rameters on the CSF between racemic ketamine 
and S(+)-ketamine.  These findings suggest that 
S(+)-ketamine is a beneficial drug for the patient 
rather than racemic ketamine to get pharmacologi-
cal action as well as racemic ketamine in the CSF 
and to reduce the incidence of adverse effects when 
administered intravenously.  S(+)-ketamine had 
similar pharmacokinetic parameters to those of 
racemic ketamine when administered epidurally. 
The concentrations of S(+)-ketamine in the plasma 
were significantly more than those in the CSF 
throughout the study period.  Its AUC in the plasma 
also was larger than that in the CSF indicating that 
S(+)-ketamine was absorbed to the plasma more 
than to the CSF.  We believed that S(+)-ketamine 
administered epidurally shifted to the CSF across 
the BBB rather than by direct penetration through 
the dura mater as well as racemic ketamine.  In-
terestingly, S(+)-ketamine had a larger AUC and 
a smaller Vdss compared with racemic ketamine 
when they had administered epidurally.  This indi-
cates that S(+)-ketamine is absorbed from the epi-
dural space to the plasma more than racemic ket-
amine and attains to higher plasma concentration 
than racemic ketamine, resulting in a signiﬁcantly 
higher Cmax of S(+)-ketamine in the plasma than 
racemic ketamine.  S(+)-ketamine had a signifi-
cantly shorter T1/2β and a smaller Vdss in the CSF 
than racemic ketamine.  This is the ﬁrst report that 
demonstrated different pharmacokinetic charac-
teristics between racemic ketamine and S(+)-ket-
Ketamine CSF levels after epidural administration
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amine.  The differences were probably elicited by 
the difference in structures of racemic mixture and 
the S(+)-isomer of ketamine.  Fast disappearance 
from the CSF and small drug distribution in the 
CSF appears to decrease the intensity of adverse ef-
fect, suggesting that S(+)-ketamine is a preferable 
agent to the patient rather than racemic ketamine 
when administered epidurally.
 We set study period on the basis of the results 
of previous study (Pedraz et al., 1991).  However, 
actual elimination half times in the CSF after intra-
venous and epidural administration of racemic ket-
amine were longer than our study period (120 min). 
The study period longer than 120 min would pro-
long the elimination half time and increase AUC. 
However, addition of points for collecting samples 
beyond 120 min after a bolus injection is not con-
sidered to affect our results on pharmacokinetic pa-
rameters because concentration curves of racemic 
ketamine in the plasma and the CSF became very 
gentle decline from 60 min after administration.
 In conclusion, racemic ketamine administered 
epidurally shifted into the plasma and passed easily 
through the BBB.  And same as racemic ketamine, 
S(+)-isomer of ketamine were absorbed from the 
epidural space to the plasma significantly more 
than to the CSF when administered epidurally. 
Passage into the CSF across the BBB through the 
systemic circulation may play a predominant role 
in the shift of ketamine from the epidural space to 
the CSF in rabbits.
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